Andreas is the CEO and co-founder of Enedra Therapeutics. He launched Enedra in collaboration with CRUK and DeepScienceVentures to design the first drugs that solve the biggest problem in cancer therapy today, tumour heterogeneity. He has led successfully two innovative companies in the cell therapy and Alzheimer’s diagnostics space. He has over 10 years experience in Pharma both as VP of Business Development at Alapis Pharma and in R&D at AstraZeneca. He received his Ph.D. in Molecular Cell biology from Cardiff University and held post-doctoral positions at the National institute for Medical Research in France (INSERM).
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
Founded by the team that pioneered data-driven design of future-proof vaccines at the Jenner Institute University of Oxford (home of the AZ vaccine), Baseimmune uses its unique computational platform to predict pathogens future mutations to design vaccines against novel and complex diseases. Joshua, its CEO, has worked on over 10 vaccines during his time at the Jenner Institute, Imperial College London and Baseimmune with two currently in human clinical trials tackling complex diseases such as HPV, Dengue and Malaria. He’s also developed a number of vaccines directly with the pharma industry.
Divya Chadha Manek
The National Institute for Health Research (NIHR) Clinical Research Network works in partnership with the National Health Service (NHS) to deliver high quality research. We support all phases of clinical research studies and trials across all disease areas. We turn the pledges in the government’s Strategy for UK Life Sciences into reality, by creating a better environment for conducting large-scale commercial contract clinical research, so that life sciences companies can place clinical studies in the UK with confidence.
Divya Chadha Manek both establishes and maintains existing strategic relationships with global and UK life sciences companies.
Facilitation is her forte: working collaboratively with companies she advises, guides and connects people so that study sponsors and CROs who deliver research, derive maximum benefit from the support provided by the NIHR - the most integrated
health research system in the world.
From her roots in commercial research delivery in NHS hospitals, Divya went on to manage a national portfolio of commercial mental health studies before progressing to her current role. With this wealth of experience under her belt she can provide expert advice on how to use the NIHR services to optimise successful delivery of clinical trials in the UK.
Rebecca is currently on part-time secondment as Head of Strategy, Value of Data - Centre for Improving Data Collaboration at NHSX.
She also serves as Director of Data and Quality Improvement, at the Cystic Fibrosis Trust since 20218. She joined the Trust in summer 2014 as the UK Cystic Fibrosis Registry Lead, and her previous experience includes clinical audit in NHS mental health, neurology and ophthalmology. From working within NHS Trusts Rebecca moved to University College London, where she managed both the National Adult and Congenital Heart Surgery Registries. Rebecca has also worked with the Healthcare Quality Improvement Partnership to publish, for the first time, consultant-level outcomes derived from 13 national clinical audits and registries across a range of specialties, including orthopaedics, bariatrics and endocrinology.
Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech.
Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-residence, where amongst other things, she leads an accelerator programme called KQ Labs, which is focused on start-ups from all over the UK who are making use of data/AI applied to health. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE (now Cytiva) in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee.
Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech.
Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.
Peter works with a long and growing list of European start-up companies, advising them on how to develop their IP strategies in a way that will build and support exit value.
He also makes sure their IP plays the part that it should within both business planning and fund raising. He has helped many of his clients successfully navigate a course through a series of funding rounds. He also sits on a number of boards for his clients so they can take full advantage of his broader commercial experience.
Building on his reputation as a leading IP strategist in the IAM Strategy 300, Peter has developed a suite of IP consultancy products addressing the need for innovation capture, IP audit and commercial strategy development for technology companies seeking private equity funding. Likewise, he has developed IP due diligence products for investors designed to evaluate and test the strength of a business’s IP. His approach provides investors with a pragmatic and cost-effective way to evaluate the IP risks associated with technology investments to ensure they get the right deal.
Peter regularly writes on the subject of IP strategy development and implementation in technology magazines such as SmallBusiness.co.uk, NS Tech and UKTN, and he has been published in the scientific journal Drug Discovery Today on the use of artificial intelligence in drug repurposing.
George Freeman is Parliamentary Under Secretary of State (Minister for Science, Research and Innovation).
Elected to Parliament in 2010 after a 15-year career founding high-growth technology companies. George has served in the last three Governments as UK Trade Envoy, the first UK Minister for Life Science, Chair of the No10 Policy Board and Minister of State at the Department for Transport.
Most recently, he led the Prime Minister’s Task Force on Innovation, Growth and Regulatory Reform (TIGRR).
He is Founder of the Big Tent Festival and Foundation, the Reform for Resilience Global Health Commission and the 2020 Conservatives Group. He is also author of Britain Beyond Brexit and the former Chair of the Conservative Policy Forum.
Steve is a serial technology entrepreneur with over 25 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors.
Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies. He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies. Steve has held CxO positions and led teams in several international businesses, supplying innovative computational biology, chemistry and semantic data integration tools. He was involved in Oxford Molecular’s IPO and the acquisition and integration of 11 companies. He is an Advisory Council member for Breast Cancer Now and UKCRC.
Markus co-founded Synthace after working as a Research Associate in Synthetic Biology at University College London where he developed novel biosynthesis methods using pathway engineering.
Prior to UCL, he was a Biotransformation Scientist at Novacta Biosystems working as part of the industrial biotechnology group that conducted more than 90 contract research projects for over 20 clients. Markus has a PhD in Plant Biochemistry from Durham.
Dr Paul Goldsmith was awarded a triple 1st from Cambridge and a clinical scholarship from Oxford. Following general medical training, he sub-specialised in neurology, before completing a PhD in a development biology lab, taking a systems biology approach to understanding human disease. He was the principal founder of DanioLabs Ltd in 2002, which utilised disease modeling for systematic drug repurposing, established discovery programmes in several areas and generated a product pipeline, the most advanced of which now has positive Phase 2 data.
He was then part of the team that reinvigorated Psychology Online Ltd, a digital health company, with a new business plan, management team and financing. He co-founded Rubrum Ltd in 2012 to provide semi-automated healthcare provision in insomnia, pain and COPD to the NHS and other markets through a proprietary online platform and was NED there until 2014. He was also co-founder of Vastrata Ltd, which focused on reprofiling and repurposing, with a virtual business model.
He also has extensive NHS operational and strategic experience, including being NHS England Northern Strategic Clinical Networks (SCN) neuro lead (to May 16), and sitting on a NHS England Urgent and Emergency Care Vanguard and the north Clinical Senate.
Paul is also a Non Executive Director of the UK Medicines & Healthcare products Regulatory Agency (MHRA).
He has in excess of 50 peer reviewed publications and patent applications.
Since 2013, Vishal Gulati is one of the most active stage agnostic digital health investors in Europe. His portfolio of over twenty companies spans a wide range of technology platforms including digital therapeutics, AI/ML, precision medicine, omics and synthetic biology.
Vishal invests directly through his syndicates or from the funds where he has a strategic relationship (Draper Esprit and Oxford Sciences Innovations).
Vishal serves on the boards of several private companies and his public appointments include committees of Cancer Research UK, the British Heart Foundation, Innovate UK/ MRC and Rueben College in Oxford.
Previously, Vishal has worked at the Wellcome Trust and Atlas Venture. Prior to this Vishal trained as a medical doctor and clinician scientist at Nuffield Department of Medicine in Oxford and Department of Medicine at Imperial College.
Alex is CSO and co-founder of Enedra Therapeutics, a recently founded biotech using AI and synthetic lethality to develop the first anti-cancer drugs that defeat tumour evolution. He has over ten years’ experience the pharma industry leading drug discovery research teams in machine learning, computational biology and genomics at Pfizer, GSK and Lonza. He received his PhD and MBA from the European Bioinformatics Institute and Cambridge University and held post-doctoral positions at the University of Kyoto and Cambridge.
Matthew Griffiths is co-founder of Concr, a computational oncology startup focused on deriving patient-specific biomarkers of treatment response. Generating these biomarkers using minimal inputs and small cohort numbers for clinical trials design is a key focus of Concr's approach. Biomedical data is highly segmented and Concr's unique solution integrates broad ranges of models and data to create an explainable, holistic model of tumour progression, applicable across patients and within pan-cancer settings.
Matthew worked with Deep Science Ventures and Accelerate@Babraham to launch Concr, and previously obtained a PhD at Cambridge University.
Dr Matthew Hallsworth is Head of External Relations for the NIHR Office for Clinical Research Infrastructure (NOCRI). He leads on external stakeholder relations, including engagement with the pharmaceutical industry.
NOCRI works with companies and other research partners to support collaboration with the UK’s expert investigators and research facilities funded by the UK Department of Health, from early-phase translational medicine through to later-phase clinical trials.
Prior to NOCRI Matthew was Head of Communications at the UK Clinical Research Collaboration – a partnership of government, charities, industry, the NHS, academia, regulators and patients focused on improving the clinical research environment in the UK.
Matthew has also had Research Management roles at the medical charity Asthma UK and for the Department of Health’s National R&D Programme.
During his earlier career Matthew was a Research Fellow in Respiratory Medicine at Guy’s & St Thomas’ Hospitals, London, where he completed his PhD on the mechanisms of inflammation in asthma and allergic disease.
Basil Jennings is the UK Lead of Palantir's Privacy & Civil Liberties Engineering Team. He is an IAPP Certified Information Privacy Professional, and has spent much of his Palantir tenure working on privacy engineering problems in large, complex healthcare processing environments, including embedding in Palantir's work helping the NHS respond to the Covid-19 pandemic.
Daniel joined Polar Capital to set up the healthcare team in 2007. He has 29 years of industry experience, comprising more than 23 years’ investment experience in the healthcare sector. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley. He also previously worked for ING Barings Furman Selz in New York following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in Biochemistry from Oxford University in 1991.
Jonathan Milner, Founder of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 60 companies and has assisted three technology companies to IPO on the London AIM Stock exchange.
Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides studying cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides.
Jonathan is Chairman of Axol Bioscience Ltd and Camallergy Ltd and non-executive director of PhoreMost Ltd, Syndicate Room Ltd, Start Codon Ltd and HealX Ltd
Indro Mukerjee is CEO of Innovate UK, the UK’s innovation agency.
He is a highly experienced technology CEO and business leader with a track record of leading innovation and technology commercialisation at businesses of all sizes across the world – from publicly listed and multinational corporations to new venture and private equity backed technology companies.
With a strong personal interest in the development of skills for industry, he cofounded the UK Electronics Skills Foundation and served on the SEMTA (now Enginuity) board for nine years, where he was also Chairman of the committee managing their investment fund.
Indro has a degree in Engineering Science from Oxford University, is a graduate of the Wharton Advanced Management Program and speaks several European languages.
Fiona is an experienced patent attorney and handles a wide variety of work in the pharmaceutical, chemical and biotechnology fields.
The majority of Fiona’s work involves working with UK clients, and she has extensive experience in developing and implementing IP strategies that are aligned with commercial objectives.
Fiona deliberately tries to avoid becoming too focused on a particular sector, believing that the underlying principles of implementing an IP strategy can be applied across many industries, and to businesses of varying sizes. That said, Fiona is recognised for her expertise in pharmaceutical life cycle management, in particular, obtaining supplementary protection certificates (SPCs) and patent term extensions for approved drugs in a number of jurisdictions worldwide. She also has a particular interest in second medical use patents and has helped a number of clients achieve commercial success with re-purposed drugs.
Fiona is a regular attendee at International Federation of Intellectual Property Attorneys (FICPI) and American Intellectual Property Law Association (AIPLA) overseas conferences and also lectures on the CIPA Administrator course. In 2017, Fiona was recognised as one of Management Today’s ’35 under 35′ for her accomplishments in intellectual property.
Debora is Enhanc3D Genomics' CEO and joined the founding team in early 2020. She has a keen interest in disruptive technologies that have potential to benefit human healthcare. She brings a wealth of experience in technology development, together with a track record of successfully delivering large-scale projects in academia and industry. In previous roles Debora led a cancer signature discovery (Director of Biomarker Discovery at Cambridge Epigenetix), directed and managed the laboratory’s research on large population studies (Head of laboratory, MRC Epidemiology, University of Cambridge) and worked on the development of the Oxford Nanopore’s technology. At Enhanc3D Genomics, Debora is leading the development of the platform, establishing the internal research programmes, strengthening the partnerships and advocating the advent of the 3D genomics era.
Enhanc3D Genomics is a functional genomics spinout company from the Babraham Institute (Cambridge, UK) leveraging a disruptive technology to profile three-dimensional (3D) genome folding at high resolution. Understanding DNA organisation and long-distance interactions allows to link gene enhancers and non-coding genetic variants to their target genes and holds promise to unlock disease-related genetics for therapeutic discovery.
A molecular biologist with 15+ years of experience in Stem Cell biology, a PhD. in cell biology and a MSc. in Biotechnology. The last 5 years I have lead a research group that focuses on the underlying mechanisms of soft tissue regeneration, mentored a dozen students and published more than 20 papers. Born and raised in academia, I recently started to make my way into the startup world. Especially interested in how to better bring innovation from the bench to the bedside, I co-founded MultiplAI Health to make preventative screening of cardiovascular diseases available to everyone in the world.
Tej Panesar is the Life Sciences Investment Director within British Patient Capital (BPC), the commercial division of the the UK’s British Business Bank focused on venture capital and UK scale-ups. Over the past 4 years he has led investments totalling £385m, including £150m into life sciences focused funds. Tej developed BPC’s life sciences investment strategy and has built out a specialist team to support BPC’s ambitions in the sector. He has a background in investment banking (Citigroup), private equity (CEO real assets fund), fintech (Crowdcube, OnBourse, Orbian) and was educated at the London School of Economics.
Manish has a doctorate in mathematical modelling with an emphasis on dealing with large, complex datasets. He is the technical architect of Jiva.ai, a new machine learning algorithm that will form the basis of a new breed of AIs.
Dr Andy Richards CBE
Andy is an entrepreneur and investor with an established track record in founding and scaling up innovative Life-science, Biotechnology and Digital Health companies in the UK. He is currently Chairman of Congenica, Abcodia, Closed Loop Medicine, Arecor and the Babraham Research Campus and is a Director of Ieso Digital Health, Owlstone Medical, and Cancer Research Technology (the commercial board of CR-UK). He is an advisor to several investment funds, including Cambridge Innovation Capital and the UCL Technology Fund, and is Chair of the CRUK Seed Fund and a Director of the Scale-Up Institute.
Andy is a Cambridge Graduate with a PhD in Chemistry and an early career spanning positions with ICI (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until its merger with Celltech in 1999 and since that time he has founded, invested in and helped to scale more than 30 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels.
Andy is passionate about science and the translation of science to do good for society. The Life-sciences and Healthcare sectors provide the perfect arena for translating science into technology that can help people around the world. He received a CBE for services to investment in life-sciences in 2015.
Nick Scott-Ram is the Chief of Data Analytics, Partnerships & Delivery and Commercial Director, SENSIGHT – Life Sciences at Sensyne Health and is also a Director at the Oxford Martin School, University of Oxford.
He has over 25 years of experience in commercial and business development in the life sciences sector, particularly in pharmaceuticals and also has an MA in Natural Sciences and a PhD in the Philosophy of Science from Cambridge University.
He has worked in blue chip life science companies such as Oxford BioMedica and PowderJect Pharmaceuticals where he was VP Corporate Affairs, responsible for strategy. Previously, he was the Director of Commercial Development at the Oxford AHSN where he was responsible for the development of strategic partnerships with major pharmaceutical companies.
Nick has extensive experience in commercial strategy, business development and pharmaceutical pricing. He led the life sciences industry position on the Biotechnology Patents Directive through the European Parliament in the 1990s. In 2001 Nick was awarded the MBE for services to biotechnology in 2001.
Thorben Seeger is the mastermind behind Lifebit’s international commercial operations. His thought leadership and strategic innovation in the clinico-genomics data field has firmly established Lifebit as the leading software technology powering precision medicine programs worldwide and a strategic partner to global firms such as AWS.
With Lifebit, Thorben strategically guides and brings to life the world’s leading national precision medicine programs, including Lifebit clients Genomics England and the Hong Kong Genome Project. In addition, he oversees strategic partnerships with pharmaceutical giants such as Boehringer Ingelheim, where Lifebit’s AI-powered platform will track global disease outbreaks and deliver novel drug targets.
With more than 14 years of experience in enterprise technology and financial solutions, prior to joining Lifebit Thorben successfully developed commercial strategies and led high-performance business development teams for global powerhouses such as Goldman Sachs, Morgan Stanley, Nomura and Duel Tech.
Julie joined Panmure Gordon in 2015 and has 20 years’ experience in Life Sciences research across a wide range of Healthcare subsectors. She previously worked at Canaccord Genuity, Piper Jaffray and Nomura having started her City career at Beeson Gregory, where she became Head of Lifesciences research. Julie has a PhD in Microbiology from the University of Kent and industry experience in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.
Clare is an experienced life sciences corporate finance and investment specialist, with significant expertise in growth funding for innovative life sciences companies in the private and public markets. Clare has been on the BIA board since January 2019 and is now seeking re-election. Clare joined LifeArc in July 2020 as Head of LifeArc Ventures, responsible for developing and implementing a strategy for LifeArc’s investments across the life sciences sector, enhancing LifeArc’s commitment to funding the translation of promising life sciences research. LifeArc’s strategic investments in innovation are a key component of its charitable model, supporting both the ability to create impact for the benefit of patients and aims to contribute to its long-term sustainability.
Clare was recently at FTSE250 listed healthcare investment company Syncona Investment Management, where she was Head of Corporate Development. She also has over 15 years’ experience in healthcare investment banking and was Managing Director and Co-Head of Healthcare and Life Sciences at Numis Securities, specialising in equity capital markets and M&A for London listed companies. Clare is also a Non-Executive Director at the Stevenage Bioscience Catalyst.
Clare has been an enthusiastic supporter of the life sciences sector and understands the opportunities and challenges that funding growing companies in the sector brings. She is currently a member of the BIA Audit Committee and intends to continue in that role.
Emma is CEO at Weatherden, a drug development route-to-market design, strategy and execution consulting group. She has built multiple companies with breakthrough therapies; and is bringing to market deep tech solutions that will transform clinical trial design efficiency alongside property ventures that will pioneer a new hybrid network of biotech innovation clusters across Britain and Europe. Prior to Weatherden, Emma worked in the life sciences division at KPMG before moving into technical advisory, followed by three years at SV Health Investors working on biotech company creation in immunology and oncology. She advises early-stage life sciences and EIS funds, is passionate about encouraging broader participation in STEM and is active mentor to young entrepreneurs.
During her time at Weatherden, Emma has witnessed first-hand the many barriers to innovation, and is passionate about accelerating better drugs to patients, equality of access to clinical trials and ensuring the UK is best placed to maintain its position on the world stage and attract more investment from overseas.
Dr Justin Whatling leads Health and Life Sciences for Palantir outside of the USA. Medical doctor by background, he has 20 years working experience in using technology and informatics to transform outcomes for patients. Justin is experienced in health operations, population health management, shared care records, and research.
Justin is a Non-Executive Director and a member of the Audit and Risk Committee for The National Institute for Health and Care Excellence, NICE. Justin is passionate about developing professionalism for health informatics, and is a Fellow or member of Finance & Audit Committee, UK Faculty of Clinical Informatics, The Chartered Institute for IT, and a past chair for BCS Health where he founded The Federation of Informatics Professionals.
Justin is a visiting professor in health informatics at University College London. He previously sat on the NHS's National Information Board and served as a non-executive director of the BMJ Publishing Group. Justin has sat on EPSRC, and HaCIRIC, a four University collaborative (Imperial, Reading, Salford, Loughborough) delivering world class research to support better healthcare through better infrastructure.
Sustaining his interest in entrepreneurship, Justin has run summer schools for health tech start-ups with BCS and
techUK, championed new standards like SMART and FHIR for App integration, helped found INTEROPen, and supported the creation of the Professional Records Standards Body.
Anthony earned a Ph.D. in molecular immunology from the University of Sheffield and received post-doctoral training at the Scripps Research Institute, where he later became associate professor of immunology. His academic work studied antibody responses against viral pathogens and prions. Anthony has co-founded 3 biotechnology companies, served as Head of Technology, Prevention Medicine at J&J and is currently CEO of AlphaBiomics Ltd. and a Partner at Skyviews Life Science, a private investment advisory.